Tarsus Pharmaceuticals saw no growth in patent filings and highest growth of 0.49% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Tarsus Pharmaceuticals’s patent filings and grants. Buy the databook here.
Tarsus Pharmaceuticals has been focused on protecting inventions in Denmark(DK) with one publication in Q2 2024
The Denmark(DK) Patent Office dominates the patent filings with nearly 100% of filings. The Denmark(DK), and Finland(FI) patent Office are among the top ten patent offices where Tarsus Pharmaceuticals is filings its patents. Among the top granted patent authorities, Tarsus Pharmaceuticals has 100% of its grants in Finland(FI).
Gilead Sciences could be the strongest competitor for Tarsus Pharmaceuticals
In terms of grant share, Tarsus Pharmaceuticals stands in ninth position among its competitors. Gilead Sciences and Tarsus Pharmaceuticals secured the top positions according to recent patent publication data.
Blepharitis related patents lead Tarsus Pharmaceuticals portfolio
Tarsus Pharmaceuticals has highest number of patents in blepharitis. For blepharitis, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
For comprehensive analysis of Tarsus Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.